Prof. PeptideProf. Peptide

November 15, 2026

CagriSema REDEFINE 9 Results: 21% Weight Loss at Lower Doses

In REDEFINE 9, CagriSema at 1.7 mg each and 1.0 mg each, two doses below the 2.4 mg each used in its main phase 3 trials, lowered body weight by 20.7% and 21.0% over 68 weeks, against 2.0% with placebo, in adults with overweight or obesity and no diabetes. The phase 3b trial was published in The Lancet Diabetes & Endocrinology on November 14, 2026 and presented at ObesityWeek 2026. It was funded by Novo Nordisk, which develops CagriSema. CagriSema is investigational and not approved anywhere.

About these figures. The trial figures are from the paper’s published abstract (Wharton S, Broholm C, Horn D, et al.), which is peer-reviewed. The treatment-regimen results, waist circumference, discontinuation rates and the FDA timing are from Novo Nordisk’s November 14 press release, and are company-reported.

What REDEFINE 9 tested

CagriSema is the once-weekly combination of the amylin analog cagrilintide with semaglutide, given by subcutaneous injection. REDEFINE 9 (ClinicalTrials.gov NCT06388187) was a randomized, double-blind within each dose level, placebo-controlled trial at 24 sites in Canada, France, Germany, the UK and the USA. It enrolled adults with a body-mass index of at least 30, or at least 27 with one or more obesity-related complication, and without diabetes. The authors say the aim was to see whether different dose levels “might support individual treatment responses and tolerability.”

309 participants were randomly assigned 2:1:2:1 to cagrilintide 1.7 mg plus semaglutide 1.7 mg (escalated over 12 weeks from 0.25 mg each), a matching placebo, cagrilintide 1.0 mg plus semaglutide 1.0 mg (escalated over 8 weeks), or its placebo, for 68 weeks, with nutrition and physical activity counselling until week 74. The two placebo groups were pooled: 104 participants on the 1.7 mg dose, 103 on the 1.0 mg dose and 102 on placebo. Mean age was 48.0 years and mean BMI 39.1; 77% were women. 291 (94%) completed the study and 254 (82%) were still on treatment at week 68. The co-primary end points were the percentage change in body weight and the proportion losing at least 5%, both at week 68.

What it reported

  • Body weight. Mean change at week 68 was −20.7% with 1.7 mg each and −21.0% with 1.0 mg each, versus −2.0% with placebo. The differences from placebo were −18.8 percentage points (95% CI −21.5 to −16.0) and −19.0 (−21.8 to −16.2), p<0.0001 for both.
  • At least 5% weight loss. 95.1% with 1.7 mg each and 96.3% with 1.0 mg each, versus 33.4% with placebo.
  • Larger losses (company-reported). Novo’s release gives at least 15% weight loss in 70.5% and 70.7% versus 5.8% with placebo, and at least 20% in 51.3% and 48.3% versus 2.7%.
  • Waist circumference (company-reported). Reductions of 17.2 cm and 17.5 cm versus 3.6 cm with placebo, a confirmatory secondary end point.

The two doses gave almost the same result, but Novo’s release says the trial “was not powered to detect differences between the two CagriSema doses,” so it does not show that the lower dose works as well as the higher one. The authors conclude that both doses were “superior to placebo at reducing bodyweight in adults with overweight or obesity, suggesting that different dose levels might support treatment flexibility.”

Two estimands

The headline figures use the efficacy estimand, which Novo describes as the “treatment effect if all participants adhered to treatment.” On the treatment-regimen estimand, which counts participants regardless of stopping treatment or using rescue weight-management treatment, Novo reports mean weight change of −19.4% (1.7 mg each) and −18.6% (1.0 mg each) versus −4.6% with placebo, differences of −14.7 and −13.9 percentage points. Both estimands are company-reported in the release; only the efficacy figures appear in the abstract.

Side effects and discontinuation

Adverse events were reported in 99% of participants on 1.7 mg each, 95% on 1.0 mg each and 91% on placebo. The authors write that most were mild or moderate and gastrointestinal, and that no deaths were reported. Novo’s release gives permanent discontinuation because of adverse events as 2.9% with 1.7 mg each, 4.9% with 1.0 mg each and 4.9% with placebo. Neither source gives rates for nausea, vomiting or other individual gastrointestinal events; the side effects reported in the larger CagriSema trials are set out in the CagriSema profile.

When is the FDA decision on CagriSema?

Novo’s release says it filed a New Drug Application with the FDA in December 2025 for CagriSema 2.4 mg/2.4 mg for weight management, with a decision expected in the fourth quarter of 2026. That application is for the 2.4 mg dose; the release does not say the 1.7 mg and 1.0 mg doses tested in REDEFINE 9 have been submitted. Until a decision, “CagriSema is not approved for use in the United States,” the release states.

How it relates to the other CagriSema trials

REDEFINE 1, the main phase 3 trial of the 2.4 mg dose in adults without diabetes, reported a 20.4% weight reduction against 3.0% with placebo over the same 68 weeks; its results and the other phase 3 trials are in the CagriSema profile. The trials enrolled different participants and no trial has compared the 2.4 mg dose with the lower doses directly. In people with type 2 diabetes, whom REDEFINE 9 excluded, a meta-analysis of six randomized trials found CagriSema’s edge over semaglutide alone was in weight rather than blood sugar, as reported in the CagriSema type 2 diabetes meta-analysis.

What this is, and isn’t

CagriSema is investigational and not approved by the FDA or any other regulator, at any dose, and these results do not make it available. FDA states that cagrilintide cannot be used in compounding under federal law, as the CagriSema profile sets out. Products sold online as research-grade CagriSema or cagrilintide are not the product tested in this trial.

Sources

This article is for informational and educational purposes only and does not constitute medical advice, a dosing recommendation or a usage recommendation.

Checked and updated